☰

Craig D. Fisher, Ph.D. - Publications

Affiliations: 
2008 Pharmacology & Toxicology University of Arizona, Tucson, AZ 
Area:
Toxicology, Pharmacology
Tree Info Grants Similar researchers PubMed Report error

15/28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2012 Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 450-60. PMID 22112382 DOI: 10.1124/Dmd.111.041095  0.766
2011 Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 2395-402. PMID 21878559 DOI: 10.1124/Dmd.111.041012  0.782
2011 Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1954-60. PMID 21737566 DOI: 10.1124/Dmd.111.040592  0.782
2010 Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 2293-301. PMID 20805291 DOI: 10.1124/Dmd.110.035006  0.733
2009 Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 2087-94. PMID 19651758 DOI: 10.1124/Dmd.109.027466  0.816
2009 Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, Cherrington NJ. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. European Journal of Pharmacology. 613: 119-27. PMID 19358839 DOI: 10.1016/J.Ejphar.2009.04.002  0.823
2008 Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis Archives of Toxicology. 82: 959-964. PMID 18488193 DOI: 10.1007/S00204-008-0312-Z  0.803
2008 Merrell MD, Jackson JP, Augustine LM, Fisher CD, Slitt AL, Maher JM, Huang W, Moore DD, Zhang Y, Klaassen CD, Cherrington NJ. The Nrf2 activator oltipraz also activates the constitutive androstane receptor. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1716-21. PMID 18474683 DOI: 10.1124/Dmd.108.020867  0.785
2008 Augustine LM, Fisher CD, Lickteig AJ, Aleksunes LM, Slitt AL, Cherrington NJ. Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats. Journal of Biochemical and Molecular Toxicology. 22: 93-100. PMID 18418895 DOI: 10.1002/Jbt.20224  0.779
2007 Lickteig AJ, Fisher CD, Augustine LM, Cherrington NJ. Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. Journal of Biochemical and Molecular Toxicology. 21: 216-20. PMID 17721935 DOI: 10.1002/Jbt.20177  0.823
2007 Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, Cherrington NJ. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 1970-8. PMID 17640958 DOI: 10.1124/Dmd.107.015107  0.833
2007 Fisher CD, Augustine LM, Maher JM, Nelson DM, Slitt AL, Klaassen CD, Lehman-McKeeman LD, Cherrington NJ. Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 995-1000. PMID 17353348 DOI: 10.1124/Dmd.106.014340  0.655
2006 Slitt AL, Cherrington NJ, Fisher CD, Negishi M, Klaassen CD. Induction of genes for metabolism and transport by trans-stilbene oxide in livers of Sprague-Dawley and Wistar-Kyoto rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1190-7. PMID 16621935 DOI: 10.1124/Dmd.105.007542  0.76
2005 Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, Ching B, Contreras P, Diaz JL, Fisher CD, Fritz LC, Gladstone P, Groessl T, Gu X, Herrmann J, et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. Journal of Medicinal Chemistry. 48: 6779-82. PMID 16250635 DOI: 10.1021/jm050307e  0.322
2004 Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. The Journal of Pharmacology and Experimental Therapeutics. 309: 634-40. PMID 14742742 DOI: 10.1124/jpet.103.062034  0.362
Low-probability matches (unlikely to be authored by this person)
2016 Wolenski FS, Shah P, Sano T, Shinozawa T, Bernard H, Gallacher MJ, Wyllie SD, Varrone G, Cicia LA, Carsillo ME, Fisher CD, Ottinger SE, Koenig E, Kirby PJ. Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage. Journal of Applied Toxicology : Jat. PMID 27397436 DOI: 10.1002/jat.3358  0.211
1998 Miura M, Micca PL, Fisher CD, Gordon CR, Heinrichs JC, Slatkin DN. Evaluation of carborane-containing porphyrins as tumour targeting agents for boron neutron capture therapy. The British Journal of Radiology. 71: 773-81. PMID 9771389 DOI: 10.1259/BJR.71.847.9771389  0.163
2016 Smith A, Calley J, Mathur S, Qian HR, Wu H, Farmen M, Caiment F, Bushel PR, Li J, Fisher C, Kirby P, Koenig E, Hall DG, Watson DE. The Rat microRNA body atlas; Evaluation of the microRNA content of rat organs through deep sequencing and characterization of pancreas enriched miRNAs as biomarkers of pancreatic toxicity in the rat and dog. Bmc Genomics. 17: 694. PMID 27576563 DOI: 10.1186/S12864-016-2956-Z  0.155
2016 Koenig EM, Fisher C, Bernard H, Wolenski FS, Gerrein J, Carsillo M, Gallacher M, Tse A, Peters R, Smith A, Meehan A, Tirrell S, Kirby P. The beagle dog MicroRNA tissue atlas: identifying translatable biomarkers of organ toxicity. Bmc Genomics. 17: 649. PMID 27535741 DOI: 10.1186/s12864-016-2958-x  0.119
1996 Miura M, Micca PL, Fisher CD, Heinrichs JC, Donaldson JA, Finkel GC, Slatkin DN. Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron-capture therapy: biodistribution and toxicity in tumor-bearing mice. International Journal of Cancer. Journal International Du Cancer. 68: 114-9. PMID 8895550 DOI: 10.1002/(SICI)1097-0215(19960927)68:1<114::AID-IJC20>3.0.CO;2-A  0.11
2018 Haynes JM, Selby JN, Abad IP, Vandekolk T, Ho JK, Lieuw WL, Leach K, Savige J, Saini S, Fisher C, Ricardo S. Induced pluripotent stem cell derived podocyte like cells as models for assessing mechanisms underlying heritable disease phenotype: initial studies using two Alport syndrome patient lines indicate impaired potassium channel activity. The Journal of Pharmacology and Experimental Therapeutics. PMID 30104322 DOI: 10.1124/jpet.118.250142  0.107
2003 CHEN L, HOGLEN N, FISHER C, VALENTINO K, CONTRERAS P. 874 IDN-6556, the first anti-apoptotic caspase inhibitor in clinical trials: tissue distribution and pharmacokinetics Hepatology. 38: 580-581. DOI: 10.1016/S0270-9139(03)80916-3  0.064
2016 Huang SC, Adhikari S, Afroze R, Brewer K, Calderwood EF, Chouitar J, England DB, Fisher C, Galvin KM, Gaulin J, Greenspan PD, Harrison SJ, Kim MS, Langston SP, Ma LT, et al. Optimization of tetrahydronaphthalene inhibitors of Raf with selectivity over hERG. Bioorganic & Medicinal Chemistry Letters. 26: 1156-60. PMID 26804230 DOI: 10.1016/j.bmcl.2016.01.049  0.061
2021 Lau RWK, Fisher C, Phan TK, Ozkocak DC, Selby J, Saini S, Mukundan S, Wise AF, Savige J, Ho Poon IK, Haynes J, Ricardo SD. Modelling X-linked Alport Syndrome With Induced Pluripotent Stem Cell-Derived Podocytes. Kidney International Reports. 6: 2912-2917. PMID 34805641 DOI: 10.1016/j.ekir.2021.07.027  0.043
2003 HOGLEN N, FISHER C, HIRAKAWA B, VALENTINO K, SHAPIRO D, CONTRERAS P. 871 IDN-6556, the first anti-apoptotic caspase inhibitor: preclinical efficacy and safety Hepatology. 38: 579-579. DOI: 10.1016/S0270-9139(03)80913-8  0.026
2006 Gonder-Frederick LA, Fisher CD, Ritterband LM, Cox DJ, Hou L, DasGupta AA, Clarke WL. Predictors of fear of hypoglycemia in adolescents with type 1 diabetes and their parents. Pediatric Diabetes. 7: 215-22. PMID 16911009 DOI: 10.1111/j.1399-5448.2006.00182.x  0.017
2019 Chong T, Palma-Diaz MF, Fisher C, Gui D, Ostrzega NL, Sempa G, Sisk AE, Valasek M, Wang BY, Zuckerman J, Khacherian C, Binder S, Wallace WD. The California Telepathology Service: UCLA's Experience in Deploying a Regional Digital Pathology Subspecialty Consultation Network. Journal of Pathology Informatics. 10: 31. PMID 31620310 DOI: 10.4103/Jpi.Jpi_22_19  0.015
2004 Fisher CD. Ethical issues in therapy: therapist self-disclosure of sexual feelings. Ethics & Behavior. 14: 105-21. PMID 15835034 DOI: 10.1207/s15327019eb1402_2  0.01
Hide low-probability matches.